Plain-English translation of NCT06833853 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
CTC-EXPRESS is a research study that tracks cancer cells and genetic material in blood samples from people with advanced breast cancer. Researchers will collect blood samples at different points during your treatment to measure how your cancer is responding. This information may help doctors better understand your disease and improve how they treat similar patients in the future.
Doctors currently use imaging scans to see how breast cancer is responding to treatment, but these scans don't always show changes quickly. This study aims to see if analyzing cancer cells and genetic material in blood samples could provide faster or more detailed information about how well treatment is working.
You likely qualify if…
You likely don't qualify if…
You will have blood drawn at your baseline visit (before or at the start of treatment) and again at your first follow-up scan appointment, as part of your normal care. Depending on your type of breast cancer, you may have additional blood draws at 4 and 8 weeks, or before other follow-up visits. Each visit requires just a few tubes of blood—the study team will collect 4 to 6 tubes at baseline and 3 to 4 tubes at follow-up visits.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States
Sponsor
Menarini Silicon Biosystems, INC
Enrollment target
~187 participants
Started
March 2026
Primary completion
October 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Marija Balic, MD, PhD, MBA
University of Pittsburgh
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.